New markers may spot ovarian cancer earlier
NCT ID NCT02326064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding a new tumor marker (HE4) and using special scoring systems (ROMA and RMI) can better tell the difference between harmless ovarian cysts and ovarian cancer. Researchers measured CA125 and HE4 levels in 221 women scheduled for ovarian cyst surgery. The goal was to improve early diagnosis and reduce uncertainty.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BENIGN OVARIAN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH de Saint Nazaire
Saint-Nazaire, 44606, France
-
CHD Vendée
La Roche-sur-Yon, 85925, France
-
CHU de Nantes
Nantes, 44093, France
-
Centre Hospitalier de Cholet
Cholet, 49300, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?